[1] Siegel RL, Miller KD, Fuchs HE and Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; https://doi.org/10.3322/caac.21708
[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249. https://doi.org/10.3322/caac.21660
[3] Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N and Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135: 584-590. https://doi.org/10.1097/CM9.0000000000002108
[4] Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ, Sharma NK, Chen H, Trifiletti DM and Zaorsky NG. Epidemiology of liver metastases. Cancer Epidemiol 2020; 67: 101760. https://doi.org/10.1016/j.canep.2020.101760
[5] Cauchy F, Fuks D and Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012; 397: 681-695. https://doi.org/10.1007/s00423-012-0911-2
[6] Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B and Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43. https://doi.org/10.1016/s1470-2045(08)70284-5
[7] Kim WW, Kim KH, Kim SH, Kim JS, Park SJ, Kim KH, Choi CS and Choi YK. Comparison of Hepatic Resection and Radiofrequency Ablation for the Treatment of Colorectal Liver Metastasis. Indian J Surg 2015; 77: 1126-1130. https://doi.org/10.1007/s12262-015-1211-1
[8] Cabibbo G, Maida M, Genco C, Alessi N, Peralta M, Butera G, Galia M, Brancatelli G, Genova C, Raineri M, Orlando E, Attardo S, Giarratano A, Midiri M, Di Marco V, Craxi A and Camma C. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013; 8: e70016. https://doi.org/10.1371/journal.pone.0070016
[9] Rivera K, Jeyarajah DR and Washington K. Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review. Front Oncol 2021; 11: 643383. https://doi.org/10.3389/fonc.2021.643383
[10] Vogl TJ, Marko C, Langenbach MC, Naguib NNN, Filmann N, Hammerstingl R and Gruber-Rouh T. Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol 2021; 31: 2242-2251. https://doi.org/10.1007/s00330-020-07253-2
[11] Cui W, Wang W, Hu Z, Dai J and Li Y. Comparison of 2 methods for prediction of liver dosimetric indices in hepatocellular cancer IMRT planning. Med Dosim 2019; 44: e80-e85. https://doi.org/10.1016/j.meddos.2019.03.004
[12] Han K and Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015; 21: 10327-10335. https://doi.org/10.3748/wjg.v21.i36.10327
[13] Bruix J, Han KH, Gores G, Llovet JM and Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015; 62: S144-156. https://doi.org/10.1016/j.jhep.2015.02.007
[14] Lencioni R and Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262: 43-58. https://doi.org/10.1148/radiol.11110144
[15] Schefter TE and Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat Oncol 2011; 21: 264-270. https://doi.org/10.1016/j.semradonc.2011.05.006
[16] Romesser PB, Neal BP and Crane CH. External Beam Radiation Therapy for Liver Metastases. Surg Oncol Clin N Am 2021; 30: 159-173. https://doi.org/10.1016/j.soc.2020.08.006
[17] Chen W, Chiang CL and Dawson LA. Efficacy and safety of radiotherapy for primary liver cancer. Chin Clin Oncol 2021; 10: 9. https://doi.org/10.21037/cco-20-89
[18] van de Lindt TN, Nowee ME, Janssen T, Schneider C, Remeijer P, van Pelt VWJ, Betgen A, Jansen EPM and Sonke JJ. Technical feasibility and clinical evaluation of 4D-MRI guided liver SBRT on the MR-linac. Radiother Oncol 2022; 167: 285-291. https://doi.org/10.1016/j.radonc.2022.01.009
[19] Thaper D, Yadav HP, Sharma D, Kamal R, Singh G, Oinam AS and Kumar V. Degree of reduction in normal liver complication probability from free-breathing to breath-hold liver SBRT: a dose-escalation strategy using radiation dose-volume effect. Biomed Phys Eng Express 2021; 8: https://doi.org/10.1088/2057-1976/ac3fe5
[20] Folkert MR and Timmerman RD. Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). Adv Drug Deliv Rev 2017; 109: 3-14. https://doi.org/10.1016/j.addr.2016.11.005
[21] He Q, Cui L, Yuan X, Wang M and Hui L. Cell identity conversion in liver regeneration after injury. Curr Opin Genet Dev 2022; 75: 101921. https://doi.org/10.1016/j.gde.2022.101921
[22] Cox JD, Stetz J and Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346. https://doi.org/10.1016/0360-3016(95)00060-c
[23] Kondo Y, Kimura O and Shimosegawa T. Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. World J Gastroenterol 2015; 21: 94-101. https://doi.org/10.3748/wjg.v21.i1.94
[24] Hawkins MA and Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006; 106: 1653-1663. https://doi.org/10.1002/cncr.21811
[25] Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK and Kim CM. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006; 29: 568-575. https://doi.org/10.1097/01.coc.0000239147.60196.11
[26] Das M. TACE plus external beam radiotherapy in liver cancer. Lancet Oncol 2018; 19: e231. https://doi.org/10.1016/S1470-2045(18)30218-3
[27] Chan MK, Kwong DL, Ng SC, Tam EK and Tong AS. Investigation of four-dimensional (4D) Monte Carlo dose calculation in real-time tumor tracking stereotatic body radiotherapy for lung cancers. Med Phys 2012; 39: 5479-5487. https://doi.org/10.1118/1.4739249
[28] Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN and Levendag PC. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006; 45: 831-837. https://doi.org/10.1080/02841860600897934
[29] Zhong NB, Lv GM and Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (>/=10 cm) hepatocellular carcinomas: A clinical study. Mol Clin Oncol 2014; 2: 839-844. https://doi.org/10.3892/mco.2014.304
[30] Miften M, Vinogradskiy Y, Moiseenko V, Grimm J, Yorke E, Jackson A, Tomé WA, Ten Haken RK, Ohri N, Méndez Romero A, Goodman KA, Marks LB, Kavanagh B and Dawson LA. Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys 2021; 110: 196-205. https://doi.org/10.1016/j.ijrobp.2017.12.290
[31] Ohri N, Tome WA, Mendez Romero A, Miften M, Ten Haken RK, Dawson LA, Grimm J, Yorke E and Jackson A. Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys 2021; 110: 188-195. https://doi.org/10.1016/j.ijrobp.2017.12.288
[32] Bae SH, Kim MS, Cho CK, Kang JK, Kang HJ, Kim YH, Shin US, Moon SM and Lee DH. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 2012; 106: 138-143. https://doi.org/10.1002/jso.23058
[33] Kimura T, Aikata H, Doi Y, Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Katsuta T, Kenjo M, Murakami Y, Awai K, Chayama K and Nagata Y. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies. Technol Cancer Res Treat 2018; 17: 1533033818783450. https://doi.org/10.1177/1533033818783450